The emergence of drugs like copyright and Semaglutide signifies a significant shift in how we approach blood sugar. These new therapies belong to a class known as GLP-1 receptor agonists, which duplicate the effects of a natural hormone that controls blood sugar levels and hunger. Initially, developed for diabetic conditions, their effectiveness in